July 2, 2025 Virogenbio announced that its investigational drug VG712 has been approved by the FDA to initiate a Phase I clinical trial for acute graft-versus-host disease (aGvHD). This represents the third approved indication for VG712, marking an important milestone in the company’s “one drug, multiple indications” strategy. The study will be conducted in collaboration with Professor Usama Gergis, Head of the Transplant and Cellular Therapy Department at Thomas Jefferson University.